Overcoming acquired resistance to PD-1 inhibitor with the addition of metformin in small cell lung cancer (SCLC)

• Published in: Cancer Immunology, Immunotherapy Immunotherapy, 2021-04, Vol.70 (4), p.961-965
• Main Authors: Kim, Yeseul, Vagia, Elena, Viveiros, Pedro, Kang, Cyra Y., Lee, Ju Young, Gim, Gahyun, Cho, Sukjoo, Choi, Horyun, Kim, Leeseul, Park, Inae, Choi, Jaeyoun, Chae, Young Kwang
• Format: Article
• Language: English
• Subjects: Antidiabetics; Antineoplastic Agents, Immunological - therapeutic use; Apoptosis; Cancer Research; CD8 antigen; Cell death; CTLA-4 protein; Cytotoxicity; Diabetes mellitus; Drug Resistance, Neoplasm - drug effects; Drug Therapy, Combination; Female; Humans; Hypoglycemic Agents - therapeutic use; Hypoxia; Immune response (cell-mediated); Immunology; Immunotherapy; Lung cancer; Lung Neoplasms - drug therapy; Lung Neoplasms - immunology; Lung Neoplasms - pathology; Lymphocytes T; Medicine; Medicine & Public Health; Metformin; Metformin - therapeutic use; Middle Aged; Nivolumab - therapeutic use; Oncology; Original; Original Article; Oxygen consumption; PD-1 protein; PD-L1 protein; Prognosis; Programmed Cell Death 1 Receptor - antagonists & inhibitors; Small cell lung carcinoma; Small Cell Lung Carcinoma - drug therapy; Small Cell Lung Carcinoma - immunology; Small Cell Lung Carcinoma - pathology; Solid tumors; Targeted cancer therapy; Tumor cells; Tumor-infiltrating lymphocytes; Tumors
• ISSN: 0340-7004; 1432-0851
• DOI: 10.1007/s00262-020-02703-8

Metformin has been widely used as the treatment of type II diabetes mellitus for its anti-hyperglycemic effect. In recent years, it has also been extensively studied for its anti-cancer effect as it diminishes immune exhaustion of CD8 + tumor-infiltrating lymphocytes (TILs). It decreases apoptosis of CD8 + TILs, thereby enhancing T cell-mediated immune response to tumor cells. Here, we present a unique case of a patient with small cell lung cancer (SCLC) who exhibited an overall partial response as per Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST 1.1) since starting metformin in combination with nivolumab therapy. Our patient had been treated with nivolumab monotherapy for 2 years until she had progression of disease. After she was started on metformin along with nivolumab therapy, she has shown a significant durable response for over 6 months. Many patients develop resistance to immunotherapy such as antibodies against cytotoxic T lymphocyte-associated protein 4 (CTLA-4), programmed cell death 1 (PD-1), and programmed cell death ligand 1 (PD-L1). Tumor hypoxia is one of the resistance factors. Signals activated by hypoxic environments in tumors are associated with decreased sensitivity to the PD-1 blockade. Metformin inhibits oxygen consumption in tumor cells in vitro and in vivo, reducing intratumoral hypoxia. These data suggest that metformin can improve susceptibility to anti-PD-1 treatment. To the best of our knowledge, our case is the first reported example demonstrating a proof-of-concept that metformin can contribute to overcoming acquired resistance to PD-1 inhibitors.